Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17483969 | 0.92 | HDAC1 (0.44) | HDAC1HDAC2HDAC3RARBMAOA | |
| SCHEMBL17483936 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2HDAC3RARBMAOA | |
| SCHEMBL17483930 | 0.88 | HDAC1 (0.54) | HDAC1HDAC2HDAC3 | |
| SCHEMBL17483931 | 0.87 | HDAC1 (0.49) | HDAC1HDAC2HDAC3MAOAMAOB | |
| SCHEMBL17483933 | 0.85 | HDAC1 (0.64) | HDAC1HDAC2HDAC3RARBMAOA | |
| SCHEMBL19682893 | 0.83 | HDAC1 (0.51) | HDAC1HDAC2HDAC3RARBMAOA | |
| SCHEMBL17483935 | 0.82 | HDAC3 (0.49) | HDAC1HDAC2HDAC3MAOAMAOB | |
| SCHEMBL17483973 | 0.82 | HDAC1 (0.47) | HDAC1HDAC2HDAC3RARBMAOA | |
| SCHEMBL19683023 | 0.79 | HDAC1 (0.49) | HDAC1HDAC2HDAC3RARBMAOA | |
| SCHEMBL17483934 | 0.79 | HDAC6 (0.65) | HDAC1HDAC2HDAC3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349540-A1 | HISTONE DEACETYLASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2017-12-07 | — | — | US | disclosed |
| WO-2016018795-A1 | HISTONE DEACETYLASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349540-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 4/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.